TOP > 外国特許検索 > Method for determination of prognosis of prostate cancer, and diagnostic agent for use in the method

Method for determination of prognosis of prostate cancer, and diagnostic agent for use in the method

外国特許コード F130007306
整理番号 05-44
掲載日 2013年4月24日
出願国 アメリカ合衆国
出願番号 22599807
公報番号 20090305299
公報番号 8080384
出願日 平成19年3月30日(2007.3.30)
公報発行日 平成21年12月10日(2009.12.10)
公報発行日 平成23年12月20日(2011.12.20)
国際出願番号 JP2007057048
国際公開番号 WO2007119606
国際出願日 平成19年3月30日(2007.3.30)
国際公開日 平成19年10月25日(2007.10.25)
優先権データ
  • 特願2006-104315 (2006.4.5) JP
  • 2007WO-JP57048 (2007.3.30) WO
発明の名称 (英語) Method for determination of prognosis of prostate cancer, and diagnostic agent for use in the method
発明の概要(英語) (US8080384)
A method for determining probability that prostate cancer will metastasize, as well as a diagnostic reagent used therefor is disclosed.
It was discovered that the percentage that NF-κB-p65/RelA has the 254th amino acid threonine which is phosphorylated is significantly higher in the prostate cancer cells in the cases where the bone metastasis was observed than in the cases where bone metastasis was not observed.
Thus, the method for determining probability that prostate cancer will metastasize comprises measuring human NF-κB-p65/RelA in which 254th amino acid threonine is phosphorylated, which human NF-κB-p65/RelA is contained in a prostate tissue separated from human.
特許請求の範囲(英語) [claim1]
1. A method for determining probability that a prostate cancer will metastasize, said method comprising measuring human NF-kappa B-p65/RelA in which 254th amino acid threonine is phosphorylated, said human NF-kappa B-p65/RelA being contained in a prostate tissue separated from human, wherein an increase in the levels of human NF-kappa B-p65/RelA in which the 254th amino acid threonine is phosphorylated in a patient compared to the levels of human NF-kappa B-p65/RelA in which the 254th amino acid threonine is phosphorylated in patients not having metastasized prostate cancer indicates an increase in the probability that a prostate cancer will metastasize.
[claim2]
2. The method according to claim 1, carried out by an immunoassay using an antibody or an antigen-binding fragment thereof, said antibody undergoing antigen-antibody reaction with human NF-kappa B-p65/RelA in which 254th amino acid threonine is phosphorylated but not undergoing antigen-antibody reaction with human NF-kappa B-p65/RelA in which 254th amino acid threonine is not phosphorylated.
[claim3]
3. The method according to claim 2, wherein said immunoassay is immunohistochemical staining.
[claim4]
4. The method according to according to any one of claims 1 to 3, wherein the metastasis is bone metastasis.
  • 発明者/出願人(英語)
  • RYO AKIHIDE
  • AOKI ICHIRO
  • SASAKI TAKESHI
  • YOKOHAMA CITY UNIVERSITY
国際特許分類(IPC)
米国特許分類/主・副
  • G01N033/574C14
※ ライセンスをご希望の方、特許の内容に興味を持たれた方は、問合せボタンを押してください。

PAGE TOP

close
close
close
close
close
close